Patents Assigned to Syngene International Limited
  • Synthetic process
    Patent number: 11332442
    Abstract: The invention generally relates to a process for preparing compounds, including Compound of Formula (I), useful as key intermediates in the preparation of compounds having ROR?t antagonist properties.
    Type: Grant
    Filed: August 12, 2020
    Date of Patent: May 17, 2022
    Assignees: Bristol-Myers Squibb Company, Syngene International Limited
    Inventors: William P. Gallagher, John Ryan Coombs, Carlos A. Guerrero, David Marcoux, Qing Shi, Candice Lee Joe, Sanjeewa Rupasinghe, Jason J. Zhu, Srinivas Kalidindi, Sathasivam Shunmugaraj, Moorthy Kandasamy, Siva Sankar Bondigela, Rajappa Vaidyanathan, Shankar Tulsidas Tendulkar, Sankar Kuppusamy, Francisco González-Bobes
  • Aryl lactam kinase inhibitors
    Patent number: 10253027
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: April 9, 2019
    Assignees: Bristol-Myers Squibb Company, Syngene International Limited, Bristol-Myers Squibb Company
    Inventors: Richard A. Hartz, Vijay T. Ahuja, Joanne J. Bronson, Carolyn Diane Dzierba, John E. Macor, Susheel Jethanand Nara, Ramkumar Rajamani
  • Biaryl kinase inhibitors
    Patent number: 10246469
    Abstract: The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's disease and schizophrenia.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: April 2, 2019
    Assignees: Bristol-Myers Squibb Company, Syngene International Limited, Bristol-Myers Squibb Company
    Inventors: Joanne J. Bronson, Ling Chen, Jonathan L. Ditta, Carolyn Diane Dzierba, Prasada Rao Jalagam, Guanglin Luo, John E. Macor, Tarun Kumar Maishal, Susheel Jethanand Nara, Ramkumar Rajamani, Ramesh Kumar Sistla, Soodamani Thangavel
  • Carbamoyloxymethyl triazole cyclohexyl acids as LPA antagonists
    Patent number: 10071078
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: September 11, 2018
    Assignees: Bristol-Myers Squibb Company, Syngene International Limited
    Inventors: Peter Tai Wah Cheng, Robert F. Kaltenbach, III, Jun Li, Jun Shi, Yan Shi, Shiwei Tao, Hao Zhang, Suresh Dhanusu, Kumaravel Selvakumar, Ramesh Babu Reddigunta, Steven J. Walker, Lawrence J. Kennedy, James R. Corte, Tianan Fang, Sutjano Jusuf
  • IDO inhibitors
    Patent number: 9790169
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: October 17, 2017
    Assignees: Bristol-Myers Squibb Company, Syngene International Limited, Bristol-Myers Squibb Company
    Inventors: James Aaron Balog, Emily Charlotte Cherney, Weiwei Guo, Audris Huang, Jay A. Markwalder, Steven P. Seitz, Weifang Shan, David K. Williams, Natesan Murugesan, Susheel Jethanand Nara, Saumya Roy, Soodamani Thangavel, Ramesh Kumar Sistla, Srinivas Cheruku, Srinivasan Thangathirupathy, Yadagiri Kanyaboina, Nagalakshmi Pulicharla
  • IDO inhibitors
    Patent number: 9765018
    Abstract: There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: September 19, 2017
    Assignees: Bristol-Myers Squibb Company, Syngene International Limited, Bristol-Myers Squibb Company
    Inventors: Jay A. Markwalder, Steven P. Seitz, James Aaron Balog, Audris Huang, Sunil Kumar Mandal, David K. Williams, Amy C. Hart, Jennifer Inghrim
  • IDO inhibitors
    Patent number: 9758492
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.
    Type: Grant
    Filed: August 26, 2014
    Date of Patent: September 12, 2017
    Assignees: Bristol-Myers Squibb Company, Syngene International Limited, Syngene International Limited
    Inventors: Jay A. Markwalder, Steven P. Seitz, James Aaron Balog, Audris Huang, Sunil Kumar Mandal, Shefali Srivastava, David K. Williams, Libing Chen